Meropenem Hikma

Meropenem, the active ingredient in Meropenem Hikma, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated skin and soft tissue infections, bacterial meningitis, severe sepsis, and hospital‑acquired pneumonia in hospitalized patients.

GNH USA supplies Meropenem Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

Complicated intra‑abdominal infections: provides rapid bacterial eradication to resolve intra‑abdominal sepsis. Complicated skin and soft tissue infections: eliminates resistant Gram‑negative and Gram‑positive pathogens. Bacterial meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections. Severe sepsis: offers extensive coverage against multidrug‑resistant organisms. Hospital‑acquired pneumonia: targets resistant respiratory pathogens in intensive‑care settings.

Meropenem may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves without intervention. - Infusion site reactions: redness, pain, or phlebitis at the injection site. - Rash: non‑specific skin eruption. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disease. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Anaphylaxis: acute hypersensitivity requiring immediate medical attention. - Severe neutropenia: marked reduction in white blood cells. - Renal impairment: worsening kidney function in susceptible individuals. - Thrombocytopenia: low platelet count leading to bleeding risk.

Before initiating Meropenem therapy, consider patient‑specific factors and monitor for potential complications.

Renal function: adjust dose in patients with impaired kidney function. Hepatic function: monitor liver enzymes during prolonged therapy. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Concomitant valproic acid: increased risk of seizures; monitor neurologic status. Therapeutic drug monitoring: consider plasma levels in severe infections or renal failure. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Valproic acid: may precipitate seizures. - Aminoglycosides: additive nephrotoxicity. - Loop diuretics: increased risk of renal dysfunction. - Warfarin: potential enhancement of anticoagulant effect. - Rifampin: may reduce meropenem concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal clearance. - Phenytoin: possible reduction in antiepileptic levels. - Oral contraceptives: decreased hormonal efficacy. - Carbapenem‑antagonistic β‑lactams: reduced antibacterial activity. - Immunosuppressants: monitor for infection risk.